Moderna nets FDA fast track designation for vaccine against coronavirus
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.